Join today and have your say! It’s FREE!

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Aug 09, 2023 4:11pm
74 Views
Post# 35580330

RE:RepliCel Life Sciences appoints Mackay as director

RE:RepliCel Life Sciences appoints Mackay as directorVery interesting timing on this announcement.  I see this as a positive development considering the critical time we are at in this Arbitration.
Very happy to have Jamie Mackay as an investor and now a Director.  Possibly they could jettison some of the existing dead wood on the Board of Directors.  


<< Previous
Bullboard Posts
Next >>